Zacks Maintains Outperform on EpiCept

Zacks is out with its report today on EpiCept

, maintaining Outperform. In its report, Zacks writes, "The Company s lead cancer candidate Ceplene has been already approved in EU and Israel for the remission maintenance of AML and a pivotal trial is planned in the US. The Company s other candidates include AmiKet for peripheral neuropathy, Azixa and Crolibulin for cancers which are all in Phase II trials. We are optimistic about EpiCept's prospect. Current valuation is low and we see a great potential for appreciation in share price as the Company continues to advance its pipeline and boosts its balance sheet." Zacks has a $2.50 PT on EPCT. At the time of posting, shares of EPCT were trading at $0.44.